Galux And Celltrion Enter Strategic Partnership To Co-Develop Next-Generation Multispecific Antibodies For Autoimmune Diseases

Aiming to accelerate drug discovery and development timelines and unlock differentiated therapeutic strategies for complex immune disorders

Galux announced a joint collaboration with Celltrion, a leading biopharmaceutical company based in Incheon, to co-develop next-generation multispecific antibodies for autoimmune diseases.

Under the agreement, the two companies will jointly discover and advance multispecific antibodies capable of modulating multiple disease-related targets simultaneously. By integrating Galux’s de novo antibody design platform and Celltrion’s extensive expertise in preclinical and clinical development, the partners aim to significantly shorten drug discovery and development timelines and improve the probability of clinical success.

“Our AI-driven protein design technology is redefining what is possible in drug discovery, moving beyond accelerating workflows to enabling the precise creation of novel therapeutic candidates with the exact structural and functional features required,” said ChaOk Seok, CEO of Galux. “We are excited to bring this technology into innovative biologics discovery through our collaboration with Celltrion.”

Multispecific antibodies are engineered to engage more than one molecular target with a single therapeutic molecule, and represent a rapidly emerging modality for treating complex immune-mediated diseases. However, traditional discovery approaches rely heavily on random screening, making it difficult to obtain diverse target-binding antibodies and even more challenging to identify optimal combinations for multispecific constructs.

Galux’s proprietary AI platform, GaluxDesign, addresses these limitations by designing antibody–target interactions at the molecular level. This allows the generation of antibodies with predefined structural and functional properties from the outset, dramatically improving precision and efficiency in multispecific antibody development. The company recently demonstrated its strength, showing more than 30% success rate in de novo antibody design across diverse targets with some of designed antibodies achieving binding affinity comparable to commercial antibody. This level of precision is recognized as one of the strongest design performances reported globally, drawing significant attention across the industry.

Celltrion has been expanding its next-generation biologics pipeline, including modalities such as multispecific antibodies and ADCs. The company has recently strengthened its open-innovation strategy, actively incorporating breakthrough external technologies to accelerate innovation in drug R&D. The collaboration with Galux is expected to create a synergistic workflow that significantly enhances the speed and success rate of multispecific antibody development.

“Advancing complex modalities such as multispecific antibodies requires innovative approaches that can overcome existing scientific limitations,” said Soo Young Lee, Vice President and Head of the New Drug Research Division at Celltrion, Inc. “Through this collaboration with Galux, we aim to lead the evolving paradigm of innovative drug R&D and contribute to strengthening Korea’s biopharma innovation ecosystem.”